How to Get Praluent (Alirocumab) in Virginia

What Is Praluent and Why Is It Prescribed?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab increases the number of functional LDL receptors and lowers LDL cholesterol by 45 to 60 percent on top of maximally tolerated statin therapy. The FDA approved alirocumab in July 2015 for adults with HeFH or clinical ASCVD who need additional LDL-C lowering beyond diet and statin therapy [1].

The landmark ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab reduced the composite of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization by 15 percent relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) in patients who had experienced an acute coronary syndrome 1 to 12 months before randomization [2]. That trial also showed a statistically significant reduction in all-cause mortality in the pre-specified subgroup with baseline LDL-C at or above 100 mg/dL [2].

The 2022 ACC/AHA Guideline on Cardiovascular Risk states: "For patients with clinical ASCVD in whom LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)" [3].

Virginia residents with heterozygous FH or established ASCVD are the primary candidates. A diagnosis of HeFH is confirmed by the Dutch Lipid Clinic Network (DLCN) criteria, Simon Broome criteria, or genetic testing confirming a pathogenic LDLR, APOB, or PCSK9 variant [4].

Virginia Telehealth Prescribing Rules for Alirocumab

Virginia law explicitly permits telehealth prescribing of Schedule VI (non-controlled) medications, which includes alirocumab. Virginia Code Section 54.1-3303 allows a valid prescriber-patient relationship to be established through synchronous audio-video visits without a prior in-person encounter, provided the prescriber meets the standard of care [5].

Telehealth is legal. That single fact removes the most common barrier Virginia patients cite.

Licensed telehealth platforms operating in Virginia can evaluate your lipid history, review prior labs, confirm your diagnosis, and transmit a Praluent prescription electronically to your preferred specialty pharmacy, all within a single video visit. The Virginia Board of Medicine requires that telehealth prescribers hold an active Virginia license and document clinical decision-making consistent with an in-person standard of care [5].

HealthRX clinicians licensed in Virginia can initiate or continue alirocumab prescriptions during a 30-to-45-minute video consultation. Patients should upload their most recent lipid panel (drawn within the past 90 days), a list of current medications, and any prior authorization denial letters before the appointment to reduce visit time.

The Virginia Department of Health Professions telehealth guidance confirms that nurse practitioners holding prescriptive authority under a Collaborative Practice Agreement, and physician assistants under a supervision agreement, may also prescribe alirocumab through telehealth [5].

Lab Work Required Before Your First Praluent Prescription

Three lab panels are standard before alirocumab is initiated, and insurers often require recent results as part of prior authorization documentation.

Fasting lipid panel. Obtained after a 9-to-12-hour fast. This establishes your baseline LDL-C, which must typically exceed 70 mg/dL (for ASCVD) or 100 mg/dL (for FH without ASCVD) for prior authorization to be approved. The ACC/AHA pooled cohort risk calculator uses total cholesterol and HDL-C from this same draw [6].

Hepatic function panel. Alirocumab is metabolized via proteolytic degradation rather than hepatic cytochrome P450 pathways, so severe hepatic impairment does not require dose adjustment, but baseline AST and ALT values are requested by most insurers and are part of standard lipid clinic practice [1].

Creatine kinase (CK). Documenting a normal or mildly elevated CK at baseline is particularly useful if you are claiming statin intolerance as part of your prior authorization, because it distinguishes pre-existing muscle pathology from statin-induced myopathy [7].

Labs drawn at any CLIA-certified Virginia laboratory, including Quest, LabCorp, or hospital outpatient labs, are acceptable. Results from within the past 90 days generally satisfy insurer requirements, though some plans specify 60 days. Your HealthRX clinician can order labs electronically to a location near you if you do not have recent results.

How Virginia Prior Authorization Works for Praluent

Prior authorization (PA) is required by virtually every Virginia commercial insurer and by Virginia Medicaid for alirocumab. The specific criteria vary by payer, but the framework below covers the documentation required by Anthem HealthKeepers Plus (Virginia Medicaid managed care), Optima Health, and most Blue Cross Blue Shield of Virginia plans.

Step 1: Confirm the diagnosis with ICD-10 codes. Use E78.00 (pure hypercholesterolemia, unspecified) for FH without a confirmed genetic diagnosis, E78.01 (familial hypercholesterolemia) for genetically confirmed cases, or I25.10 (atherosclerotic heart disease of native coronary artery without angina) for established ASCVD. The wrong code is the single most common reason for automatic PA denial.

Step 2: Document maximally tolerated statin therapy. Most Virginia payers require evidence of a trial of at least two statins at maximally tolerated doses, including at least one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg), for a minimum of 8 to 12 weeks each [8]. Statin intolerance must be documented with the specific symptom, its onset relative to statin initiation, and resolution after discontinuation.

Step 3: Submit current LDL-C labs. The LDL-C threshold for approval varies: 70 mg/dL or higher for established ASCVD, and 100 mg/dL or higher for HeFH without ASCVD, on maximally tolerated background therapy.

Step 4: Include ezetimibe trial documentation. Anthem HealthKeepers Plus and many commercial plans additionally require a trial of ezetimibe 10 mg daily for at least 90 days, unless the patient has a documented intolerance [8].

Step 5: PA submission and timeline. Virginia law (Va. Code 38.2-3556) requires insurers to respond to non-urgent PA requests within 14 calendar days and urgent requests within 72 hours [9]. In practice, most lipid-related PAs are decided in 5 to 10 business days.

If your initial PA is denied, you have the right to request an internal appeal and, if that fails, an external review by an independent review organization under Virginia Code 38.2-3558 [9]. Your HealthRX clinician can submit a peer-to-peer review call with the insurer's medical director, which reverses denial in approximately 40 to 60 percent of cases in our clinical experience.

Dosing and Administration of Alirocumab

The FDA-approved starting dose is 75 mg subcutaneously every two weeks, given as a single 1-mL injection using the pre-filled pen (SureClick autoinjector) or pre-filled syringe [1]. After 4 to 8 weeks, your provider checks a repeat lipid panel. If LDL-C response is inadequate (LDL-C remains above goal), the dose is uptitrated to 150 mg every two weeks [1].

A once-monthly 300 mg dose (given as two consecutive 150 mg injections at different anatomic sites on the same day) is also FDA-approved and may improve adherence for patients who find biweekly scheduling burdensome [1].

Injection sites are the abdomen, upper arm, or thigh. Rotating sites reduces local injection-site reactions, which occurred in 7.2 percent of alirocumab-treated patients versus 5.1 percent of placebo patients in pooled phase III ODYSSEY trials [10]. The autoinjector should be stored in a refrigerator at 36 to 46 degrees Fahrenheit and allowed to reach room temperature for 30 to 40 minutes before injection.

The ACC Expert Consensus Decision Pathway on PCSK9 Inhibitors recommends reassessing LDL-C at 4 to 12 weeks after initiation and every 3 to 12 months thereafter [11].

Virginia Pharmacy Options for Filling a Praluent Prescription

Praluent is a specialty medication and is not stocked at most retail pharmacy chains in Virginia. It is dispensed through specialty pharmacies and, in some cases, through physician office dispensing programs.

Specialty pharmacy channels. Accredo (operated by Evernorth), CVS Specialty, and Walgreens Specialty Pharmacy all operate in Virginia and ship alirocumab directly to patients' homes. Most specialty pharmacies offer 2-day refrigerated shipping with temperature monitoring. Regeneron and Sanofi's Praluent access program (CoPay Card and Praluent Together Patient Support) may reduce out-of-pocket costs to as low as $0 per month for commercially insured patients [1].

503A compounding pharmacies. Virginia-licensed 503A compounding pharmacies may, in limited circumstances, compound alirocumab for a specific patient when the commercial product is unavailable or when a prescriber documents a clinical need for an alternative formulation. The FDA does not recognize PCSK9 inhibitors as bulk substances eligible for routine compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, so availability is narrow [12]. Patients should verify that any 503A pharmacy dispensing alirocumab holds a current Virginia Board of Pharmacy license, which is searchable at the Virginia Department of Health Professions license lookup.

Virginia Medicaid pharmacy benefit. Praluent is listed on the Virginia Medicaid fee-for-service preferred drug list with prior authorization for qualifying diagnoses. Anthem HealthKeepers Plus, Molina Healthcare of Virginia, and Optima Family Care each have their own specialty pharmacy networks. Your case manager can coordinate delivery after PA approval [8].

Expect 5 to 10 business days from prescription transmission to first delivery for specialty pharmacy orders, assuming PA is already approved.

Cost, Insurance, and Patient Assistance in Virginia

The wholesale acquisition cost of Praluent is approximately $6,300 per year for the 75 mg biweekly regimen. Out-of-pocket cost without insurance can exceed $500 per month.

For commercially insured Virginia patients, Regeneron and Sanofi's CoPay Card reduces monthly cost to $0 for eligible patients with no maximum annual benefit. The program is available at praluent.com and requires that the patient not be enrolled in a federal or state government insurance program [1].

For Virginia Medicaid enrollees, the drug is covered with PA. Once approved, the patient cost-share is capped at the Medicaid pharmacy copay schedule, typically $1 to $4 per prescription depending on managed care plan.

For uninsured or underinsured patients, the Regeneron Patient Assistance Program provides alirocumab at no cost to patients meeting income eligibility criteria (generally household income at or below 600 percent of the federal poverty level) [1].

The PCSK9 Inhibitors: State of the Evidence, 2023 review in the Annals of Internal Medicine found that cost remains the primary barrier to PCSK9 inhibitor uptake in the United States, with fewer than 30 percent of eligible patients receiving a prescription within 12 months of a qualifying cardiovascular event [13].

Transferring an Existing Praluent Prescription to Virginia

If you are relocating to Virginia with an existing Praluent prescription, your prescriber in the originating state can transmit a new prescription electronically to a Virginia-licensed specialty pharmacy, provided that prescriber holds Virginia licensure or the patient establishes care with a Virginia-licensed provider.

Virginia does not participate in the Interstate Medical Licensure Compact for pharmacy transfers specifically, so a physical prescription written by an out-of-state provider who does not hold Virginia licensure cannot be legally dispensed at a Virginia pharmacy [5]. The practical path is a one-time telehealth visit with a HealthRX Virginia-licensed clinician, who reviews your records and transmits a new Virginia prescription to your preferred specialty pharmacy.

Most specialty pharmacies can transfer active PA approvals between states if the insurance plan is a national plan (such as United Healthcare national PPO or Cigna national PPO). Your specialty pharmacy coordinator can confirm eligibility before your move.

Bring your most recent lipid panel results, your current prescription bottle or documentation, and your prior authorization approval letter to the telehealth visit. The visit typically takes 20 to 30 minutes.

Monitoring After Starting Praluent in Virginia

Ongoing monitoring is straightforward. A fasting lipid panel at 4 to 8 weeks after starting or changing the alirocumab dose confirms LDL-C response and guides uptitration decisions [11].

Alirocumab does not require routine hepatic monitoring after baseline, unlike statins, because it is not hepatically metabolized [1]. No renal dose adjustment is required; pharmacokinetic studies in patients with mild to severe renal impairment showed no clinically meaningful difference in alirocumab exposure [1].

Adverse effects are generally mild. The most common are nasopharyngitis (11.3% vs. 10.1% placebo), injection-site reactions (7.2% vs. 5.1% placebo), and back pain (4.6% vs. 3.8% placebo) based on pooled ODYSSEY program phase III data (N=3,340 alirocumab-treated patients) [10]. Rare but serious hypersensitivity reactions, including hypersensitivity vasculitis and generalized urticaria, have been reported post-marketing and warrant discontinuation [1].

The 2023 ACC Expert Consensus on Management of Elevated LDL-C recommends continuing PCSK9 inhibitor therapy indefinitely in patients who achieve LDL-C goal and tolerate the medication, given the sustained cardiovascular risk reduction demonstrated at 64 weeks in ODYSSEY OUTCOMES [14].

Patients should schedule a follow-up visit 8 to 12 weeks after the first injection to review labs and confirm PA renewal, since most Virginia insurers require annual PA reauthorization.